---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-25-000008"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T23:02:37.922138+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mineralys reports FY2024 net loss $177.8M; cash $198.2M; pivotal data expected Q1-Q2 2025

## Summary
- Net loss for FY2024 was $177.8M vs $71.9M in FY2023; R&D spend $168.6M vs $70.4M.
- Cash, equivalents and investments $198.2M as of Dec 31, 2024; expected to fund operations through Q1 2026.
- Topline data from pivotal Advance-HTN trial expected March 2025; Launch-HTN Phase 3 data in mid first half 2025.
- Enrollment in Explore-CKD Phase 2 complete; topline data anticipated Q2 2025.
- Initiating Phase 2 trial for lorundrostat in moderate-to-severe OSA and hypertension in Q1 2025.

## SEC filing metadata
- accession: 0001933414-25-000008
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/0001933414-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/mlys-20250212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-25-000008
- JSON: https://secwatch.observer/filing/0001933414-25-000008.json
- Plain text: https://secwatch.observer/filing/0001933414-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.